期刊名称：DRUG TESTING AND ANALYSIS
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
As the incidence of drugs escalates in 21st century living, their detection and analysis have become increasingly important. Sport, the workplace, crime investigation, homeland security, the pharmaceutical industry and the environment are just some of the high profile arenas in which analytical testing has provided an important investigative tool for uncovering the presence of extraneous substances.
In addition to the usual publishing fare of primary research articles, case reports and letters, Drug Testing and Analysis offers a unique combination of; ‘How to’ material such as ‘Tutorials’ and ‘Reviews’, Speculative pieces (‘Commentaries’ and ‘Perspectives', providing a broader scientific and social context to the aspects of analytical testing), ‘Annual banned substance reviews’ (delivering a critical evaluation of the methods used in the characterization of established and newly outlawed compounds) and a bibliographical listing that pulls together all of the current literature in the field on a bimonthly basis.
Rather than focus on the application of a single technique, Drug Testing and Analysis employs a unique multidisciplinary approach to the field of controversial compound determination. Papers discussing chromatography, mass spectrometry, immunological approaches, 1D/2D gel electrophoresis, to name just a few select methods, are welcomed where their application is related to any of the six key topics listed below.
Features and Coverage
The journal will focus on six key topics
Sports doping
Illicit/recreational drugs use
e.g. drug-testing methods by employers
Pharmaceuticals
e.g. pharmacokinetics, metabolism studies, characterization and detection of new therapeutics, natural products, biosimilars and generics
Toxico-pathology
e.g. determining posthumous drug presence
Forensics/homeland security
e.g. determining the presence of controlled substances at a crime scene or use by perpetrators, analysis of compounds with potential use as biological or chemical warfare agents
Environment
e.g. wastewater analysis, determination of pollutants/contaminants, etc.
Readership
Sports scientists • Clinical Physicians • Toxicologists • Forensic scientists • Employers operating drug screening programmes • Law enforcement agencies • Homeland security agencies • Pharmacists • Biochemists • Microbiologists • Organic chemists • Separation scientists • Policy makers in industry and government
Keywords
Doping, sport, homeland security, therapeutics, natural products, drug testing, analytical chemistry, mass spectrometry, chromatography, electrophoresis, ELISA, drug abuse, proteomics, gene doping, athlete, journal, online journal, Wiley InterScience
Abstracting and Indexing Information
CAS: Chemical Abstracts Service (CAS)
EMBASE (Elsevier)
Focus On: Sports Science and Medicine (Thomson ISI)
MEDLINE/PubMed (NLM)
Science Citation Index Expanded™ (Thomson ISI)
SCOPUS (Elsevier)
Web of Knowledge (Thomson ISI)
Web of Science (Thomson ISI)
Instructions to Authors
Author Guidelines
For additional tools visit Author Resources - an enhanced suite of online tools for Wiley InterScience journal authors, featuring Article Tracking, E-mail Publication Alerts and Customized Research Tools.
Copyright Transfer Agreement
Permission Request Form
The National Institutes of Health Public Access Initiative
Author Guidelines
General
Manuscript Submission
Copyright and Permissions
English Editing
Presentation of Papers
Writing Abstracts
Reference Style
Illustrations and ChemDraw Rules
Graphical Table of Contents
Colour Policy
Citing EarlyView Articles
Conventions Adopted by DTA
Article Formats Published in DTA
Cover Graphic Opportunities
Further Information
General
Drug Testing and Analysis (DTA) is devoted to the publication of papers dealing with the development and application of techniques for the determination of controlled or controversial substances.
Papers must clearly be of scientific value in the field and will be submitted to two independent referees. Contributions must be in English and must not have been published elsewhere, and authors must agree not to communicate the same material for publication to any other journal. It is in the author's interest to ensure accurate and consistent presentation and thus avoid publication delays. There are no page charges.
Return to Top
Manuscript Submission
All papers must be submitted via the online system. Drug Testing and Analysis operates an online submission and peer review system that allows authors to submit articles online and track their progress via a web interface. Please read the remainder of these instructions to authors and then click http://mc.manuscriptcentral.com/dta to navigate to the Drug Testing and Analysis online submission site.
IMPORTANT: Please check whether you already have an account in the system before trying to create a new one. If you have reviewed or authored for the journal in the past year it is likely that you will have created an account.
File types. Preferred formats for the text and tables of your manuscript are .doc, .rtf, .ppt, .xls. LaTeX files may be submitted provided that an .eps or .pdf file is provided in addition to the source files. Figures may be provided in .tiff or .eps format.
Please note: This journal does not accept Microsoft Word 2007 documents at this time. Please use Word's "Save As" option to save your document as a .doc file type. If you try to upload a Word 2007 document in Manuscript Central you will be prompted to save .docx files as.doc files.
INITIAL SUBMISSION
NON-LATEX USERS: Editable source files must be uploaded at this stage. Tables must be on separate pages after the reference list, and not be incorporated into the main text. Figures should be uploaded as separate figure files.
LATEX USERS: For reviewing purposes you should upload a single .pdf that you have generated from your source files. You must use the File Designation "Main Document" from the dropdown box.
REVISION SUBMISSION
NON-LATEX USERS: Editable source files must be uploaded at this stage. Tables must be on separate pages after the reference list, and not be incorporated into the main text. Figures should be uploaded as separate figure files.
LATEX USERS: When submitting your revision you must still upload a single .pdf that you have generated from your now revised source files. You must use the File Designation "Main Document" from the dropdown box. In addition you must upload your TeX source files. For all your source files you must use the File Designation "Supplemental Material not for review". Previous versions of uploaded documents must be deleted. If your manuscript is accepted for publication we will use the files you upload to typeset your article within a totally digital workflow.
Return to Top
Copyright and Permissions
Authors must sign, scan and upload to the online system:
a Copyright Transfer Agreement with original signature(s) - without this we are unable to accept the submission, and
permission grants - if the manuscript contains extracts, including illustrations, from other copyright works (including material from on-line or intranet sources) it is the author's responsibility to obtain written permission from the owners of the publishing rights to reproduce such extracts using the Wiley Permission Request Form
The Copyright Transfer Form and the Permissions Form should be uploaded as “Supplementary files not for review” with the online submission of your article.
If you do not have access to a scanner, further instructions will be given to you after acceptance of the manuscript.
To enable the publisher to disseminate the author's work to the fullest extent, the author must sign a Copyright Transfer Agreement, transferring copyright in the article from the author to the publisher, and submit the original signed agreement with the article presented for publication. Submission of a manuscript will be held to imply that it contains original unpublished work and is not being submitted for publication elsewhere at the same time. Submitted material will not be returned to the author, unless specifically requested
Return to Top
English Editing
Papers must be in English. Oxford English Dictionary or American spelling is acceptable, provided usage is consistent within the manuscript.
Manuscripts that are written in English that is ambiguous or incomprehensible, in the opinion of the Editor, will be returned to the authors with a request to resubmit once the language issues have been improved. This policy does not imply that all papers must be written in "perfect" English, whatever that may mean. Rather, the criterion will require that the intended meaning of the authors must be clearly understandable, i.e., not obscured by language problems, by referees who have agreed to review the paper.
Authors for whom English is a second language may choose to have their manuscript professionally edited before submission to improve the English. A list of independent suppliers of editing services can be found at http://www.blackwellpublishing.com/bauthor/english_language.asp Japanese authors can also find a list of local English improvement services at http://www.wiley.co.jp/journals/editcontribute.html All services are paid for and arranged by the author, and use of one of these services does not guarantee acceptance or preference for publication.
Return to Top
Presentation of papers
Manuscript style. Use a standard font of the 12-point type: Times, Helvetica, or Courier is preferred. It is not necessary to double-line space your manuscript.
Tables must be on separate pages after the reference list, and not be incorporated into the main text. Figures should be uploaded as separate figure files.
During the submission process you must enter 1) the full title 2) the short title of up to 70 characters 3) names and affiliations of all authors and 4) the full address, including email, telephone and fax of the author who is to check the proofs.
Include the name(s) of any sponsor(s) of the research contained in the paper, along with grant number(s) and details of any conflicts of interest, be they personal, commercial, political, academic or financial.
Enter an abstract of no more than 250 words for all articles. Please see the guidance below on acceptable abstract writing for DTA
Keywords. Authors should prepare no more than 5 keywords for their manuscript.
Return to Top
Writing Abstracts
An abstract is a concise summary of the whole paper, not just the conclusions. The abstract should be no more than 250 words and convey the following:
1. An introduction to the work. This should be accessible by scientists in any field and express the necessity of the experiments executed
2. Some scientific detail regarding the background to the problem
3. A summary of the main result
4. The implications of the result
5. A broader perspective of the results, once again understandable across scientific disciplines
It is crucial that the abstract convey the importance of the work and be understandable without reference to the rest of the manuscript to a multidisciplinary audience. Abstracts should not contain any citation to other published works.
Reference Style
References should be cited by superior numbers and listed at the end of the paper in the order in which they appear in the text. Authors should cite available published work. If necessary, cite unpublished or personal work in the text but do not include them in the references list. Journal titles should be italicized and abbreviated in accordance with the “Chemical Abstracts Service Source Index” (CASSI; no commas appear in the journal names).
Examples for Journals
[1] P.J. Weaver, A.M.-F. Laures, J.-C. Wolff. Investigation of the advanced functionalities of a hybrid quadrupole orthogonal acceleration time-of-flight mass spectrometer. Rapid. Commun. Mass Spectrom. 2007, 21 , 2451.
Examples for Books
[2] K. Schmidt-Rohr, H.W. Spiess. Multidimensional Solid-State NMR and Polymers. Academic Press, London, 1994.
[3] V. Sklenar. in NMR Applications in Biopolymers, (Eds: J.W. Finley, S. J. Schmidt, A. S. Serianni). Plenum, New York, 1990, pp. 63-70.
Return to Top
Illustrations and ChemDraw Rules
Upload each figure as a separate file in either .tiff or .eps format, with the figure number and the top of the figure indicated. Compound figures e.g. 1a, b, c should be uploaded as one figure. Tints are not acceptable. Lettering must be of a reasonable size that would still be clearly legible upon reduction, and consistent within each figure and set of figures. Where a key to symbols is required, please include this in the artwork itself, not in the figure legend. All illustrations must be supplied at the correct resolution:
Black and white and colour photos - 300 dpi
Graphs, drawings, etc - 800 dpi preferred; 600 dpi minimum
Combinations of photos and drawings (black and white and colour) - 500 dpi
Tables should be part of the the main document and should be placed after the references. If the table is created in excel the file should be uploaded separately.
Chemical structures should be prepared in ChemDraw either 80mm (onecolumn)or175mm (twocolumn) widths. However, the one-column format should be used whenever possible as this allows greater flexibility in the layout of the manuscript.Use this ChemDraw Download or use the following settings:
|
Drawing settings |
Text settings |
|
chain angle |
120° |
font |
Arial |
|
bond spacing |
18% of length |
size |
12 pt |
|
fixed length |
17 pt |
|
|
bond width |
2 pt |
Preferences |
|
line width |
0.75 pt |
units |
points |
|
margin width |
2 pt |
tolerances |
5 pixels |
|
hash spacing |
2.6 pt |
|
|
|
Bold width |
2.6 pt |
|
Authors using different structural drawing programs should choose settings consistent with those above. Compound numbers should be bold, but not atom labels or captions.
Return to Top
Graphical Table of Contents
DTA’s table of contents will be presented in graphical form with a brief abstract.
The table of contents entry must include the article title, the authors' names (with the corresponding author indicated by an asterisk), no more than 80 words or 3 sentences of text summarising the key findings presented in the paper and a figure that best represents the scope of the paper. (see the section on abstract writing for more guidance).
Table of contents entries should be submitted to Manuscript Central in one of the generic file formats and uploaded as ‘Supplementary material for review’ during the initial manuscript submission process.
The image supplied should fit within the dimensions of 50mm x 60mm, and be fully legible at this size.
Examples for arranging the text and figures as well as paper title and authors' names are shown below.
Return to Top
Colour policy
Colour is free of charge for authors submitting the following article types:
• Review
• Mini-review
• Tutorial
• Perspective
• Annual Banned-Substance Review
The cost of printing colour illustrations for Research Articles may be charged to the author however they may feature in colour on-line free of charge. For colour charge scales please contact Journals Production
Return to Top
Citing EarlyView Articles
To include the DOI in a citation to an article, simply append it to the reference as in the following example:
R. K. Harris, A. Nordon, K. D. M. Harris, Rapid. Commun. Mass Spec. 2007, DOI: 10.1002/rcm.21464.
To link to an article from the author’s homepage, take the DOI (digital object identifier) and append it to "http://dx.doi.org/" as per following example:
DOI 10.1002/DTA.20941, becomes http://dx.doi.org/10.1002/DTA.20941.
Return to Top
Conventions adopted by DTA
Nomenclature. Authors should conform to nomenclature, symbols, abbreviations and procedures adopted by ASTM. SI units are preferred; if more commonly used units are adopted, conversion factors should be given at their first occurrence.
Description of Experimental Methods. The Experimental section should be precise and give all details necessary for repeating the work. Particular attention should be given to methods used for calibration of instruments and spectra when electron spectroscopic data are presented.
Abbreviations. All abbreviations should be defined the first time they are used.
Ethical Guidance.DTA requires that the conditions under which human and animal experiments are performed are consistent with recognised standards. Authors must make it clear that the procedures they used were as humane as possible and complied with the guidelines for animal care of their institutions or with national/international guidelines. Studies involving human subjects must be carried out with the formal approval of the relevant Ethical Committee, and evidence of such approval must be provided on request.
Return to Top
Article formats published in DTA
Annual Banned-Substance Review
Tutorial
Review
Mini-review
Cornerstone Articles
Perspective
Research Article
Application Notes
Short Communications
Case report/letters
Current Awareness
Podcast/Webinar
Annual Banned-Substance Review. This annual review will provide an in depth critique of popular known banned substances and assess and review the current state of detection methods. The annual banned substance review will be coordinated by the journal editors and published annually in the first issue of each volume. Authors inclined to contribute may contact the Editor in Chief.
Tutorials. Tutorial Articles provide a source of information that goes beyond that conveyed in a normal research article. Topics should be presented at an introductory level suitable for non-experts with maximum attention being given to clarity of expression, freedom from jargon, and high quality figures. Articles should stimulate as well as inform the readers. Tutorials must be accompanied by an abstract and contain less than 50 references.
Mini-reviews.The criteria for a mini review is the same as a full critical review albeit less extensive in length and scope. Mini-reviews contain no more than 50 references.
Cornerstone Articles. Cornerstone papers are an occasional article type bringing previously published seminal work to the attention of the Drug Testing and Analysis audience. Such features may include previously unavailable English translations of influential research or pioneering articles from complimentary disciplines that have made a significant contribution to the field of drug testing.
Perspectives. A Perspective is a lightly referenced scholarly opinion piece about current or future directions in a field. A Perspective can serve to assess the science directly concerned with a particular topic or report on relevant issues that may arise from the discipline (for example, policy, effects on society, regulatory issues and controversies). Perspectives that address interdisciplinary research areas or experimental results with significance to a broader audience are of particular interest to the Editors. The Perspective should be accompanied by an abstract and generally contain less than 50 references. Perspectives will be subject to screening for appropriateness and accuracy but will not undergo the traditional peer review model.
Research Articles. There are no formal limits on the page extent for Research Articles. Please see the above section for rules pertaining to format and presentation.
Application notes. Short articles reporting on innovative applications, "kitchen tips" from a laboratory setting or technology. Application notes in DTA are not advertorials but are welcomed from both product manufacturers and independent authors. DTA recommends for conciseness that each Application note is written in an accessible, easy-to-read style, less than 3 journal pages in length including illustrations (approx 2000 words including 3 illustrations) and contain less than 20 references. Application Notes will be screened for scientific accuracy and appropriateness.
Short communications. Short papers containing important, new, definitive information of sufficient significance to warrant publication may be submitted to the journal as a Short Communication. These submissions should be concise, representing either a preliminary report or a complete account of a significant, short research contribution. Technique or methods papers may also be accepted in this category. The submitted paper should be less than 2000 words with a maximum combination of five figures and/or tables, and a maximum of 20 references.
Case reports/Letters. Case reports and letters to the editor will publish under the category of Correspondence and must not contain more than 20 references. Articles in this category will be subject to screening for scientific accuracy but will not undergo traditional peer review models, they require no accompanying abstract.
Current AwarenessThese bibliographies are designed to keep researchers and clinicians up-to-date with latest developments in their area of research and are compiled as a result of manual scanning of the literature providing a continuous update of appropriate papers in chemistry, medicine and the life sciences on a worldwide basis. For ease of use, each bibliography will be divided into sections including for example sports doping, recreational drugs, and forensic toxicology.
Bibliographies will appear bimonthly both in print and online at Wiley Online Library (www.interscience.com). Both PDF and HTML files will be available to facilitate browsing and enable multi-publisher reference linking via CrossRef. This will allow readers to move from a selected reference to the abstract or complete publication (dependent upon appropriate subscription) including papers by other publishers and on other servers. MEDLINE links will also be available.
Podcast/webinars.DTA will supplement the traditional publishing models by providing its audience with Podcasts and Webinars. Descriptions of these methods of dissemination can be found on Wikipedia.
Podcast
Webinar
The editors invite authors to participate in this initiative. Proposals can be sent directly to the Wiley journal editor for consideration. ptrevorr@wiley.com. Note: these materials will be monitored for scientific accuracy but will not undergo the traditional processes of peer review.
Return to Top
Cover Artwork Opportunities
Drug Testing and Analysiswill feature a cover graphic for the purpose of highlighting an article featured within the issue. Authors wishing to explore this opportunity are advised to supply a suitable illustration for this purpose. The selection process for cover illustrations will be the determined by the Editors.
Return to Top
Please note that you must own the copyright to reproduce images, if you do not own the images then permission must be granted by the copyright holder.
Reproductions of the cover in print and electronic formats and additional copies of the journal featuring bespoke cover artwork may be obtained from the publisher. Please direct any enquiries to ptrevorr@wiley.com
Further Information
For accepted manuscripts the publisher will supply proofs to the submitting author prior to publication. This stage is to be used only to correct errors that may have been introduced during the production process. Prompt return of the corrected proofs, preferably within two days of receipt, will minimise the risk of the paper being held over to a later issue. Offprints and copies of the journal may be ordered. There is no page charge to authors.
Manuscript accepted for publication? If so, check out our suite of tools and services for authors and sign up for:
Article Tracking
E-mail Publication Alerts
Personalization Tools
Editorial Board
EDITOR-IN-CHIEF
Prof. Mario Thevis
Professor for Preventive Doping Research
German Sport University Cologne
Institute of Biochemistry
Am Sportpark Müngersdorf 6
50933 Cologne
Germany
e-mail: m.thevis@biochem.dshs-koeln.de
ASSOCIATE EDITORS
Dr Tiia Kuuranne
Doping Control Laboratory
United Medix Laboratories Ltd.
Höyl mötie 14
00380 Helsinki
Finland
e-mail: tiia.kuuranne@medix.fi Prof. Adrian Franke
Natural Products & Cancer Biology Program
Cancer Research Center of Hawai‘i
1236 Lauhala St.
Honolulu, HI 96813, USA
e-mail: adrian@crch.hawaii.edu
Dr Ray Kazlauskas
National Measurement Institute, NMI
1 Suakin Street
AU - Sydney, NSW 2073
Australia
e-mail: ray.kazlauskas@measurement.gov.au Dr Andrew Kicman
Head of Research & Development
Drug Control Centre
King’s College, London
UK
e-mail: andrew.kicman@kcl.ac.uk
ADVISORY BOARD
Dr Ronald Algius
LaborKrone
Germany Per Bjorklov
DrugtestScandinavia
Sweden
Yves Bonnaire
Laboratoire des Courses Hippiques
Verrieres le Buisson, France Prof. Francesco Botrè
WADA-ISO17025 Antidoping
Rome, Italy
Dr Simon Brandt
Liverpool John Moores University
Liverpool, UK Prof. David Cowan
King's College
London, UK
Prof. Olaf H. Drummer
Monash University
Melbourne, Australia Prof. Howell GM Edwards
University of Bradford
Bradford, UK
Dr Bryan Finkle
NFL advisor, Partnership for Clean Competition
Montana, USA Dr Stefan Franz
Roche Pharma (Schweiz)
Switzerland
Claire George
Concateno Cozart
Oxford, UK Prof. Gary Green
UCLA Division of Sports Medicine
Pacific Palisades, USA
Prof. Ulrich Griesser
University of Innsbruck
Innsbruck, Austria Lindsay Hadfield
Concateno Medscreen Limited
London, UK
Dr Caroline Hatton
Sports Anti-doping Science Consultant
California, USA Prof. James Heffron
University College Cork
Cork, Ireland
Prof. Peter Hemmersbach
Norwegian Doping Control Laboratory
Norway Prof. Richard I.G. Holt
University of Southampton
Southampton, UK
Dr Harald John
Bundeswehr Institute of Pharmacology and Toxicology
Munich, Germany Dr James Kerwin
Los Angeles, USA
Dr Les King
Basingstoke, UK Prof. Hans Maurer
Institute of Experimental and Clinical Pharmacology and Toxicology
Saarland University, Germany
Dr Thomas Moehring
Thermo Fisher Scientific
Bremen, Germany Dr Christine Moore
Immunalysis Corporation
California, USA
Dr LJ Mostert
Van-Weel-Bethesda Hospital
The Netherlands Prof Dr Frank Musshoff
University Bonn
Bonn, Germany
Dr David H. Perlman
Princeton University
NJ, USA Anya Pierce
PPM Consultants
Dublin, Ireland
Dr Robert Plumb
Waters Corporation
Milford, USA Dr Mathias Schaefer
University of Cologne
Cologne, Germany
Dr David Sheehan
University College Cork
Cork, Ireland Dr Alain Verstraete
Ghent University Hospital
Ghent, Belgium
Dr Terence S.M. Wan
Racing Laboratory, HKJC
Hong Kong, China
| 
